Matinas BioPharma Holdings Inc (NYSE MKT:MTNB) — Market Cap & Net Worth
Market Cap & Net Worth: Matinas BioPharma Holdings Inc (MTNB)
Matinas BioPharma Holdings Inc (NYSE MKT:MTNB) has a market capitalization of $4.09 Million ($4.09 Million) as of September 17, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #29059 globally and #5941 in its home market, demonstrating a 23.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Matinas BioPharma Holdings Inc's stock price $0.70 by its total outstanding shares 6406191 (6.41 Million). Also see Matinas BioPharma Holdings Inc asset portfolio for a full breakdown of the balance sheet.
Matinas BioPharma Holdings Inc Market Cap History: 2015 to 2026
Matinas BioPharma Holdings Inc's market capitalization history from 2015 to 2026. Data shows change from $272.26 Million to $4.51 Million (-31.45% CAGR). Also see Matinas BioPharma Holdings Inc (MTNB) cash flow conversion for how efficiently the company converts equity into cash flow.
Matinas BioPharma Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Matinas BioPharma Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Matinas BioPharma Holdings Inc stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
63.19x
Matinas BioPharma Holdings Inc's market cap is 63.19 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $371.56 Million | $149.69K | -$15.49 Million | 2482.24x | N/A |
| 2018 | $190.58 Million | $119.75K | -$14.08 Million | 1591.52x | N/A |
| 2019 | $727.10 Million | $89.81K | -$17.37 Million | 8095.83x | N/A |
| 2020 | $435.62 Million | $158.33K | -$22.45 Million | 2751.30x | N/A |
| 2021 | $323.51 Million | $33.00K | -$23.28 Million | 9803.41x | N/A |
| 2022 | $160.15 Million | $3.19 Million | -$21.00 Million | 50.24x | N/A |
| 2023 | $69.25 Million | $1.10 Million | -$22.94 Million | 63.19x | N/A |
Competitor Companies of MTNB by Market Capitalization
Companies near Matinas BioPharma Holdings Inc in the global market cap rankings as of September 17, 2026. Review MTNB tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Matinas BioPharma Holdings Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Matinas BioPharma Holdings Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Matinas BioPharma Holdings Inc's market cap moved from $272.26 Million to $ 4.51 Million, with a yearly change of -31.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.51 Million | +20.14% |
| 2025 | $3.75 Million | +14.90% |
| 2024 | $3.27 Million | -95.28% |
| 2023 | $69.25 Million | -56.76% |
| 2022 | $160.15 Million | -50.50% |
| 2021 | $323.51 Million | -25.74% |
| 2020 | $435.62 Million | -40.09% |
| 2019 | $727.10 Million | +281.51% |
| 2018 | $190.58 Million | -48.71% |
| 2017 | $371.56 Million | -17.14% |
| 2016 | $448.43 Million | +64.71% |
| 2015 | $272.26 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Matinas BioPharma Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.09 Million USD |
| MoneyControl | $4.09 Million USD |
| MarketWatch | $4.09 Million USD |
| marketcap.company | $4.09 Million USD |
| Reuters | $4.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an… Read more